SCHEMBL2907919

SCHEMBL2907919

O=C(Cl)C=Cc1c(F)cccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.56
HPGD P15428 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 1/20 0.50
ALOX12 P18054 1/20 0.50
ATM Q13315 1/20 0.50
MDM4 O15151 1/20 0.49
MAPT P10636 1/20 0.49
MDM2 Q00987 1/20 0.49
KMT2A Q03164 1/20 0.49
KRAS P01116 1/20 0.46
RAB9A P51151 5/20 0.45
NFE2L2 Q16236 2/20 0.45
NPC1 O15118 2/20 0.45
HTT P42858 1/20 0.45
POLB P06746 1/20 0.44
MAOB P27338 1/20 0.44
ALDH1A1 P00352 1/20 0.42
ALOX15 P16050 1/20 0.42
CES2 O00748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907918 1.00 ABCG2 (0.56) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL3574508 0.83 ABCG2 (0.59) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL3574506 0.83 ABCG2 (0.59) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL22046679 0.82 ABCG2 (0.39) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL1226433 0.81 ABCG2 (0.58) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL1226435 0.81 ABCG2 (0.58) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL5750500 0.79 ABCG2 (0.56) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL5750497 0.79 ABCG2 (0.56) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL167101 0.79 ABCG2 (0.56) ABCG2HPGDSMN1; SMN2LMNAALOX12
SCHEMBL167102 0.79 ABCG2 (0.56) ABCG2HPGDSMN1; SMN2LMNAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513258-B2 Cinnamoyl-piperazine derivatives and their use as par-1 antagonists PIERRE FABRE MEDICAMENT (FR) 2013-08-20 US disclosed
US-20120232097-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS PEREZ MICHEL (FR) 2012-09-13 US disclosed
US-8217046-B2 Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists PIERRE FABRE MEDICAMENT (FR) 2012-07-10 US disclosed
EP-2041104-B1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PF MEDICAMENT (FR) 2010-08-18 EP disclosed
US-20090176803-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2009-07-09 US disclosed
EP-2041104-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS Pierre Fabre Medicament (FR) 2009-04-01 EP disclosed
WO-2007147824-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2007-12-27 WO disclosed
US-20040181062-A1 Benzimidazole cyclooxygenase-2 inhibitor PFIZER INC 2004-09-16 US disclosed
US-6713482-B2 SUCH AS (E)-1-(2-PYRIDYL)-2-STYRYL-1H-BENZIMIDAZOLE; ANTIINFLAMMATORY AND ANALGESIC AGENTS; PROSTAGLANDIN INHIBITORS PFIZER INC. 2004-03-30 US disclosed
US-20030013886-A1 Benzimidazole cyclooxygenase-2 inhibitors OKUMURA YOSHIYUKI (JP) 2003-01-16 US disclosed
EP-0937722-B1 Benzimidazole derivatives as cyclooxygenase-2 inhibitors PFIZER (US) 2002-07-03 EP disclosed
US-6310079-B1 NON-STEROIDAL ANTIINFLAMMATORY AGENTS PFIZER INC. 2001-10-30 US disclosed
EP-0937722-A1 Benzimidazole derivatives as cyclooxygenase-2 inhibitors PFIZER INC. (US) 1999-08-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176803-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS F2R, F2RL1, F2RL3 ABCG2 1163/4885HPGD 663/4885SMN1; SMN2 4599/4885
US-20120232097-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS F2R, F2RL1, F2RL3 ABCG2 1163/4885HPGD 663/4885SMN1; SMN2 4599/4885
US-20030013886-A1 Benzimidazole cyclooxygenase-2 inhibitors PTGS1, CBR1, CBR3 ABCG2 301/4885HPGD 719/4885SMN1; SMN2 3664/4885
US-20040181062-A1 Benzimidazole cyclooxygenase-2 inhibitor PTGS1, CBR1, CBR3 ABCG2 341/4885HPGD 762/4885SMN1; SMN2 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.